| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Ginkgo Bioworks Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$76.25 |
| 52 Week High | US$1,276.00 |
| 52 Week Low | US$173.20 |
| Beta | 1.07 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -96.26% |
Recent News & Updates
Recent updates
Shareholder Returns
| DNA * | MX Chemicals | MX Market | |
|---|---|---|---|
| 7D | 0% | 2.2% | 1.2% |
| 1Y | n/a | -22.0% | 3.9% |
Return vs Industry: Insufficient data to determine how DNA * performed against the MX Chemicals industry.
Return vs Market: Insufficient data to determine how DNA * performed against the MX Market.
Price Volatility
| DNA * volatility | |
|---|---|
| DNA * Average Weekly Movement | n/a |
| Chemicals Industry Average Movement | 4.1% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in MX Market | 6.2% |
| 10% least volatile stocks in MX Market | 2.7% |
Stable Share Price: DNA *'s share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine DNA *'s volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 1,218 | Jason Kelly | www.ginkgobioworks.com |
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
Ginkgo Bioworks Holdings, Inc. Fundamentals Summary
| DNA * fundamental statistics | |
|---|---|
| Market cap | Mex$8.88b |
| Earnings (TTM) | -Mex$17.69b |
| Revenue (TTM) | Mex$3.63b |
2.4x
P/S Ratio-0.5x
P/E RatioIs DNA * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DNA * income statement (TTM) | |
|---|---|
| Revenue | US$184.34m |
| Cost of Revenue | US$36.46m |
| Gross Profit | US$147.88m |
| Other Expenses | US$1.05b |
| Earnings | -US$897.68m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -16.11 |
| Gross Margin | 80.22% |
| Net Profit Margin | -486.98% |
| Debt/Equity Ratio | 0% |
How did DNA * perform over the long term?
See historical performance and comparison